- Home
- BNGO vs TENX Comparison
BNGO vs TENX Comparison
Compare BNGO & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNGO
- TENX
- Stock Information
- Founded
- BNGO 2003
- TENX 1967
- Country
- BNGO United States
- TENX United States
- Employees
- BNGO N/A
- TENX N/A
- Industry
- BNGO Biotechnology: Laboratory Analytical Instruments
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- BNGO Industrials
- TENX Health Care
- Exchange
- BNGO Nasdaq
- TENX Nasdaq
- Market Cap
- BNGO 24.3M
- TENX 25.8M
- IPO Year
- BNGO 2018
- TENX N/A
- Fundamental
- Price
- BNGO $2.93
- TENX $5.85
- Analyst Decision
- BNGO Buy
- TENX Strong Buy
- Analyst Count
- BNGO 5
- TENX 3
- Target Price
- BNGO $7.33
- TENX $16.00
- AVG Volume (30 Days)
- BNGO 102.6K
- TENX 23.2K
- Earning Date
- BNGO 08-14-2025
- TENX 08-19-2025
- Dividend Yield
- BNGO N/A
- TENX N/A
- EPS Growth
- BNGO N/A
- TENX N/A
- EPS
- BNGO N/A
- TENX N/A
- Revenue
- BNGO $28,464,000.00
- TENX N/A
- Revenue This Year
- BNGO N/A
- TENX N/A
- Revenue Next Year
- BNGO $15.54
- TENX N/A
- P/E Ratio
- BNGO N/A
- TENX N/A
- Revenue Growth
- BNGO N/A
- TENX N/A
- 52 Week Low
- BNGO $2.68
- TENX $3.25
- 52 Week High
- BNGO $37.09
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- BNGO 30.33
- TENX 40.47
- Support Level
- BNGO $2.92
- TENX $5.80
- Resistance Level
- BNGO $3.09
- TENX $6.25
- Average True Range (ATR)
- BNGO 0.14
- TENX 0.24
- MACD
- BNGO -0.03
- TENX -0.04
- Stochastic Oscillator
- BNGO 8.33
- TENX 10.31
About BNGO Bionano Genomics Inc.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.